Merck reports better-than-expected Q4 results, but full-year guidance misses expectations
Merck reported Q4 results that beat Wall Street estimates but gave full-year guidance below expectations.
For the last three months of 2025, Merck reported:
Adjusted earnings per share of $2.04, compared to the $2.01 analysts polled by FactSet were expected.
Revenue of $16.4 billion, compared to the $16.02 billion Wall Street was expecting.
For the full year in 2026, Merck expects:
Annual adjusted earnings per share to land between $5.00 and $5.15, lower than the $5.27 analysts are currently expecting.
Annual revenues to hit between $65.5 billion and $67.0 billion, the midpoint of which is below the $67.4 billion analysts are penciling in.